Brandon Ayres, MD
Ophthalmology · Bala Cynwyd, PANPI 1710985460
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Alcon at 27.0% of the total. 2025 is the largest year on record at $242,472, 2.6 times the $94,313 reported in 2019. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,007 payments — averaging $922.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$251K
- Bausch & Lomb Americas Inc.$122K
- Dompe US, Inc.$84K
- Sight Sciences, Inc.$70K
- Sun Pharmaceutical Industries Inc.$60K
- Tarsus Pharmaceuticals, Inc.$60K
- plus $282K from 37 others
Across 77 payments — averaging $4242.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avedro Inc.$140K
- Glaukos Corporation$110K
- Sight Sciences, Inc.$77K
What the payments were for
- Consulting fees$443,13548%
- Speaking & faculty fees$422,63145%
- Travel & lodging$26,8083%
- Food & beverage$29,2183%
- Education$400%
- Gifts$370%
- Other$7,4751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$90,929
- MIEBO$85,949
- Oxervate$80,570
- CEQUA$58,846
- XDEMVY$49,041
- AcrySof IQ VIVITY$48,665
- AcrySof$46,075
- Clareon$43,685
- AcrySof IQ VIVITY IOL$40,275
- TRYPTYR$39,919
- OMNI(R) SURGICAL SYSTEM (US)$32,339
- SION SURGICAL INSTRUMENT$32,206
- AcrySof IQ PanOptix UV IOL$27,725
- VUITY$25,797
- VERACITY SURGICAL$21,585
- AcrySof IQ PanOptix$19,350
- TEARCARE SYSTEM$18,739
- ARTEVO 800$18,528
- IOLMaster 700$14,165
- LOTEMAX SM$13,933
How this compares
$929,344 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 80 | $91,560 |
| RestasisCyclosporine | 60 | $85,578 |
| Cyclosporine | 82 | $49,063 |
| Loteprednol Etabonate | 266 | $48,734 |
| Prednisolone Acetate | 1,156 | $45,808 |
| XdemvyLotilaner | 20 | $36,187 |
| XiidraLifitegrast | 25 | $31,345 |
| Difluprednate | 53 | $13,756 |
| LumiganBimatoprost | 25 | $12,781 |
| Lotemax SmLoteprednol Etabonate | 39 | $12,666 |
| TyrvayaVarenicline Tartrate | 12 | $7,771 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $7,004 |
| ValacyclovirValacyclovir Hcl | 117 | $5,310 |
| BesivanceBesifloxacin Hcl | 18 | $4,418 |
| Fluorometholone | 41 | $3,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $122,270 | $122,905105 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $53,536 | $104,386113 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Besivance | $8,255 | $65,817323 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $59,545 | $36,18720 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $91 | $7,77112 claims |
| AlconSimbrinza | $251,312 | $3,60718 claims |
| Eyevance Pharmaceuticals LLCFlarex | $2,485 | $2,01811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Bala Cynwyd
- Richard TippermanBala Cynwyd$111K
- Michael ProBala Cynwyd$35K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.